Modeling, design and synthesis of new heteroaryl ethylenes active against the MCF-7 breast cancer cell-line.

A dataset of 50 compounds was used to generate a QSAR model and to design 9 new heteroaryl ethylenes. These compounds were synthesized, tested in vitro and a significant agreement with in silico predictions observed. Studies using Laser Scanning Confocal Microscopy pointed out that the compounds may act by different mechanisms.

[1]  Enrique Fernández-Blanco,et al.  Naïve Bayes QSDR classification based on spiral-graph Shannon entropies for protein biomarkers in human colon cancer. , 2012, Molecular bioSystems.

[2]  J. Buolamwini,et al.  Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. , 2005, Current cancer drug targets.

[3]  G. Higa.  Breast cancer: beyond the cutting edge , 2009, Expert opinion on pharmacotherapy.

[4]  Vasant Ranade.  Molecular Interaction Fields , 2006 .

[5]  C. Fortuna,et al.  Photobehaviour and DNA interaction of styrylquinolinium salts bearing thiophene substituents , 2011, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[6]  D. Condorelli,et al.  In vitro antitumor activities of 2,6-di-[2-(heteroaryl)vinyl]pyridines and pyridiniums. , 2002, Bioorganic & medicinal chemistry.

[7]  P. Cozzi,et al.  Recent anticancer cytotoxic agents. , 2004, Current medicinal chemistry. Anti-cancer agents.

[8]  Giuseppe Musumarra,et al.  Design and synthesis of trans 2-(furan-2-yl)vinyl heteroaromatic iodides with antitumour activity. , 2008, Bioorganic & medicinal chemistry.

[9]  A. Trovato-Salinaro,et al.  Design, synthesis and in vitro antitumour activity of new heteroaryl ethylenes. , 2012, European journal of medicinal chemistry.

[10]  K. McMasters,et al.  Excellent outcomes with adjuvant toremifene or tamoxifen in early stage breast cancer , 2010, Cancer.

[11]  Synthesis and NLO properties of new trans 2-(thiophen-2-yl)vinyl heteroaromatic iodides. , 2011, Organic & biomolecular chemistry.

[12]  Sonia Arrasate,et al.  MIANN models in medicinal, physical and organic chemistry. , 2013, Current topics in medicinal chemistry.

[13]  V. V. Kleandrova,et al.  Rational drug design for anti-cancer chemotherapy: multi-target QSAR models for the in silico discovery of anti-colorectal cancer agents. , 2012, Bioorganic & medicinal chemistry.

[14]  H. González-Díaz.  Editorial [Hot Topic: QSAR/QSPR Models as Enabling Technologies for Drug & Targets Discovery in: Medicinal Chemistry, Microbiology-Parasitology, Neurosciences, Bioinformatics, Proteomics and Other Biomedical Sciences (Guest Editor: Humberto Gonzalez Diaz)] , 2012 .

[15]  T. Beckers,et al.  New small-molecule tubulin inhibitors , 2001 .

[16]  C. Biberger,et al.  Studies on Heterocyde‐Based Pure Estrogen Antagonists a , 1995, Annals of the New York Academy of Sciences.

[17]  G. Musumarra,et al.  Design, synthesis and in vitro antitumor activity of new trans 2-[2-(heteroaryl)vinyl]-1,3-dimethylimidazolium iodides. , 2004, Bioorganic & medicinal chemistry.

[18]  Giuseppe Musumarra,et al.  Potentialities of multivariate approaches in genome‐based cancer research: identification of candidate genes for new diagnostics by PLS discriminant analysis , 2004 .

[19]  G. Musumarra,et al.  Design, synthesis and biological evaluation of trans 2-(thiophen-2-yl)vinyl heteroaromatic iodides. , 2010, Bioorganic & medicinal chemistry.

[20]  F. Rojo,et al.  Targeted therapies in breast cancer. , 2008, Seminars in diagnostic pathology.

[21]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[22]  R. Chari,et al.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[23]  Carmen L. Lewis,et al.  Effectiveness of a patient and practice‐level colorectal cancer screening intervention in health plan members , 2011, Cancer.

[24]  A. Gomtsyan,et al.  Heterocycles in drugs and drug discovery , 2012, Chemistry of Heterocyclic Compounds.

[25]  C. Hansch.  QSAR in cancer chemotherapy. , 1979, Il Farmaco; edizione scientifica.

[26]  Nceba Gqaleni,et al.  ACS Symposium Series , 2013 .

[27]  Adeel Malik,et al.  Databases and QSAR for Cancer Research , 2009 .

[28]  K. Wanner,et al.  Methods and Principles in Medicinal Chemistry , 2007 .

[29]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[30]  Humberto González Díaz,et al.  QSAR model for alignment‐free prediction of human breast cancer biomarkers based on electrostatic potentials of protein pseudofolding HP‐lattice networks , 2008, J. Comput. Chem..

[31]  V. V. Kleandrova,et al.  Chemoinformatics in anti-cancer chemotherapy: multi-target QSAR model for the in silico discovery of anti-breast cancer agents. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  K. Gelmon,et al.  Adjuvant targeted therapy in early breast cancer , 2009, Cancer.